Iomai reports success with traveler’s diarrhea patch

Iomai has racked up more positive data for its vaccine patch to prevent traveler's diarrhea. A new study details that only three of 59 volunteers who used the patch experienced a severe or moderate bout of diarrhea compared to 24 of 111 who were given a placebo. The three patch users who did get sick reported that the bout lasted for only a half day. No side effects were reported.

"These results suggest that the Iomai patch has the potential to fundamentally change the way we approach prevention of this disease, an ailment against which we now have very few weapons," says Dr. Herber L. DuPont, professor and director of the Center for Infectious Diseases at The University of Texas School of Public Health. 

Iomai recently agreed to a takeover by Intercell.

- here's Iomai's release
- read the story in CTV

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.